bioMérieux received an overall score of 10.13 out of a possible 12.00 points, the highest overall Frost & Sullivan Competitive Metrics Score in the U.S. Rapid Pharmaceutical Manufacturing Microbiology Tests Market. The Market Leadership Award is given to a company that displays overall excellence in the market leadership process, including the identification of market challenges, drivers and restraints, brand recognition as well as strategy development and methods of addressing market trends.
bioMérieux ranked highest in 3 out of 4 categories, which included market positioning and growth, innovative performance, growth strategy, and leveragable assets. The company´s overall score was more than two points higher than the combined average score of the other Tier I companies evaluated. bioMérieux was also acknowledged for its unparalleled product quality and customer support in the industry, noting that bioMérieux systems offer automated solutions that increase workflow and reduce employee training times.
“Delivering rapid testing methods to help our biopharma customers ensure the quality of their manufacturing processes is our priority,” said Alexandre Mérieux, Corporate Vice President, Industrial Microbiology. “I am honored to see the efforts of our North American team recognized by Frost & Sullivan.”
“The shift from traditional culture methods to rapid microbiology testing is critical to address the needs of today´s pharmaceutical industry,” confirmed Madhu Sharma, Ph.D., Senior Research Analyst at Frost & Sullivan.
The Frost & Sullivan award applauded bioMérieux for continuously enhancing its product offer to meet customer needs. bioMérieux´s recent launches include DiversiLab™ Strain Typing systems for same-day investigation results, BioBall® quantitative bacterial cultures and 3P® clean room and Isolator media.
|
